Last reviewed · How we verify
Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders
This is a study to evaluate the safety and efficacy of Miltenyi CliniMACS® CD34 Reagent System to promote engraftment of haploidentical CD34+ selected cells combined with single unit umbilical cord blood transplant for treatment of high-risk hematologic disorders.
Details
| Lead sponsor | University of Colorado, Denver |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 150 |
| Start date | Thu Oct 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Feb 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Hematologic Disorders
Interventions
- Miltenyi CliniMACS® CD34 Reagent System
Countries
United States